These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27707566)

  • 1. Simultaneous control of glycemic, blood pressure, and lipid significantly reduce the risk of renal progression in diabetes patients.
    Chang PY; Chien LN; Lin YF; Chiu WT; Chiou HY
    Eur J Intern Med; 2016 Dec; 36():87-92. PubMed ID: 27707566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Annual deterioration of renal function in hypertensive patients with and without diabetes.
    Polonia J; Azevedo A; Monte M; Silva JA; Bertoquini S
    Vasc Health Risk Manag; 2017; 13():231-237. PubMed ID: 28721063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
    Mottl AK; Buse JB; Ismail-Beigi F; Sigal RJ; Pedley CF; Papademetriou V; Simmons DL; Katz L; Mychaleckyj JC; Craven TE
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1693-1702. PubMed ID: 30361335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National survey: Evaluation of cardiovascular risk factors in Thai patients with type 2 diabetes and chronic kidney disease after the development of cardiovascular disease.
    Changsirikulchai S; Sangthawan P; Janma J; Sripaiboonkij N; Rattanamongkolgul S; Thinkhamrop B
    Nephrology (Carlton); 2018 Jan; 23(1):53-59. PubMed ID: 27608176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function deterioration in adult patients with type-2 diabetes.
    Bramlage P; Lanzinger S; Hess E; Fahrner S; Heyer CHJ; Friebe M; Buschmann I; Danne T; Holl RW; Seufert J
    BMC Nephrol; 2020 Jul; 21(1):312. PubMed ID: 32727401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between medication adherence and clinical outcomes in patients with chronic kidney disease: a prospective cohort study.
    Tangkiatkumjai M; Walker DM; Praditpornsilpa K; Boardman H
    Clin Exp Nephrol; 2017 Jun; 21(3):504-512. PubMed ID: 27438073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of medical therapies on retinopathy progression in type 2 diabetes.
    ; ; Chew EY; Ambrosius WT; Davis MD; Danis RP; Gangaputra S; Greven CM; Hubbard L; Esser BA; Lovato JF; Perdue LH; Goff DC; Cushman WC; Ginsberg HN; Elam MB; Genuth S; Gerstein HC; Schubart U; Fine LJ
    N Engl J Med; 2010 Jul; 363(3):233-44. PubMed ID: 20587587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry.
    Luk AO; Li X; Zhang Y; Guo X; Jia W; Li W; Weng J; Yang W; Chan WB; Ozaki R; Tsang CC; Mukhopadhyay M; Ojha AK; Hong EG; Yoon KH; Sobrepena L; Toledo RM; Duran M; Sheu W; Q Do T; Nguyen TK; Ma RC; Kong AP; Chow CC; Tong PC; So WY; Chan JC;
    Diabet Med; 2016 Sep; 33(9):1230-9. PubMed ID: 26511783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
    Tong L; Adler S
    Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
    Yamout H; Perkovic V; Davies M; Woo V; de Zeeuw D; Mayer C; Vijapurkar U; Kline I; Usiskin K; Meininger G; Bakris G
    Am J Nephrol; 2014; 40(1):64-74. PubMed ID: 25059406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices.
    Corcillo A; Pivin E; Lalubin F; Pitteloud N; Burnier M; Zanchi A
    Swiss Med Wkly; 2017; 147():w14459. PubMed ID: 28695552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated with Poor Glycemic and Lipid Levels in Ambulatory Diabetes Mellitus Type 2 Patients in Asmara, Eritrea: A Cross-Sectional Study.
    Achila OO; Ghebretinsae M; Kidane A; Simon M; Makonen S; Rezene Y
    J Diabetes Res; 2020; 2020():5901569. PubMed ID: 32090121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.
    Ismail-Beigi F; Craven TE; O'Connor PJ; Karl D; Calles-Escandon J; Hramiak I; Genuth S; Cushman WC; Gerstein HC; Probstfield JL; Katz L; Schubart U;
    Kidney Int; 2012 Mar; 81(6):586-94. PubMed ID: 22166848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive antihypertensive treatment and serum lipid lowering therapy are necessary to prevent deterioration of the renal function even in elderly type 2 diabetic patients with persistent albuminuria.
    Narita T; Kakei M; Ito S
    Gerontology; 2002; 48(5):302-8. PubMed ID: 12169796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
    Bays HE; Brinton EA; Triscari J; Chen E; Maccubbin D; MacLean AA; Gibson KL; Ruck RA; Johnson-Levonas AO; O'Neill EA; Mitchel YB
    Vasc Health Risk Manag; 2015; 11():165-72. PubMed ID: 25750540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control.
    Betônico CC; Titan SM; Correa-Giannella ML; Nery M; Queiroz M
    Clinics (Sao Paulo); 2016 Jan; 71(1):47-53. PubMed ID: 26872083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
    Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
    Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
    Kobayashi K; Toyoda M; Hatori N; Furuki T; Sakai H; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Yamamoto H; Machimura H; Chin K; Hishiki T; Takihata M; Aoyama K; Umezawa S; Minamisawa K; Aoyama T; Hamada Y; Suzuki Y; Hayashi M; Hatori Y; Sato K; Miyakawa M; Tamura K; Kanamori A
    J Diabetes Investig; 2021 Jan; 12(1):74-81. PubMed ID: 32506833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
    Ruilope L; Hanefeld M; Lincoff AM; Viberti G; Meyer-Reigner S; Mudie N; Wieczorek Kirk D; Malmberg K; Herz M
    BMC Nephrol; 2014 Nov; 15():180. PubMed ID: 25407798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood Pressure, and Low-Density Lipoprotein-Cholesterol on Cardiovascular Diseases in Chinese Primary Care Patients With Type 2 Diabetes Mellitus: A Population-Based Retrospective Cohort Study.
    Wan EYF; Fung CSC; Yu EYT; Chin WY; Fong DYT; Chan AKC; Lam CLK
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.